Investigational New Drugs

, Volume 30, Issue 6, pp 2303–2317

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

  • Michael Millward
  • Timothy Price
  • Amanda Townsend
  • Christopher Sweeney
  • Andrew Spencer
  • Shawgi Sukumaran
  • Angie Longenecker
  • Lonnie Lee
  • Ana Lay
  • Girish Sharma
  • Robert M. Gemmill
  • Harry A. Drabkin
  • G. Kenneth Lloyd
  • Saskia T. C. Neuteboom
  • David J. McConkey
  • Michael A. Palladino
  • Matthew A. Spear
PHASE I STUDIES

Summary

Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique proteasome inhibition, toxicology and efficacy profiles, suggested utility in combining it with an HDAC inhibitor such as vorinostat. Thus, in this study in vitro studies assessed the potential utility of combining marizomib and vorinostat, followed by a clinical trial with the objectives of assessing the recommended phase 2 dose (RP2D), pharmacokinetics (PK), pharmacodynamics (PD), safety and preliminary anti-tumor activity of the combination in patients. Experimental Design Combinations of marizomib and vorinostat were assessed in vitro. Subsequently, in a Phase 1 clinical trial patients with melanoma, pancreatic carcinoma or Non-small Cell Lung Cancer (NSCLC) were given escalating doses of weekly marizomib in combination with vorinostat 300 mg daily for 16 days in 28 day cycles. In addition to standard safety studies, proteasome inhibition and pharmacokinetics were assayed. Results Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma. In the clinical trial, 22 patients were enrolled. Increased toxicity was not seen with the combination. Co-administration did not appear to affect the PK or PD of either drug in comparison to historical data. Although no responses were demonstrated using RECIST criteria, 61% of evaluable patients demonstrated stable disease with 39% having decreases in tumor measurements. Conclusions Treatment of multiple tumor cell lines with marizomib and vorinostat resulted in a highly synergistic antitumor activity. The combination of full dose marizomib with vorinostat is tolerable in patients with safety findings consistent with either drug alone.

Keywords

Proteasome Marizomib NPI-0052 Melanoma Lung cancer Pancreatic cancer 

References

  1. 1.
    Ahn KS, Sethi G, Chao TH, Neuteboom S, Chaturvedi M, Palladino M, Younes A, Aggarwal B (2007) Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through downmodulation of NF-kB regulated gene products. Blood 110:2286–2295PubMedCrossRefGoogle Scholar
  2. 2.
    Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao T, Neuteboom S, Richardson P, Palladino M, Anderson K (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8:407–419PubMedCrossRefGoogle Scholar
  3. 3.
    Price T, Millward M, Mainwaring P, Harrison S, Catley L, Townsend A, Sukumaran S, Longenecker A, Palladino MA, Lloyd GK, Neuteboom STC, Padrik P, Spear MA, Spencer A (2009) A 2 arm phase 1 clinical trial with NPI-0052 (a novel proteasome inhibitor). EORTC-AACR-NCI Int Conf Molecular Targets and Cancer TherapeuticGoogle Scholar
  4. 4.
    Hofmeister CC, Richardson P, Zimmerman T, Spear MA, Palladino MA, Longenecker AM, Cropp GF, Lloyd GK, Hannah AL, Anderson K (2009) Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). J Clin Oncol 27:15 s (8505)Google Scholar
  5. 5.
    Hamlin PA, Aghajanian C, Younes A, Hong DS, Palladino MA, Longenecker AM, Lloyd GK, Hannah AL, Spear MA, Kurzrock R (2009) First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052. J Clin Oncol 27:15 s (3516)Google Scholar
  6. 6.
    Taylor MD, Liu Y, Nagji AS, Theodosakis N, Jones DR (2010) Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg 139(5):1224–1232, 1232.e1PubMedCrossRefGoogle Scholar
  7. 7.
    Zolinza (vorinostat) (2006) Prescribing information. Merck, Inc., Whitehouse Station, New Jersey, USAGoogle Scholar
  8. 8.
    Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J (2009) Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 113:4289–4299PubMedCrossRefGoogle Scholar
  9. 9.
    Wray C, Fournier KF, Sundi D, Marquis LM, McConkey DJ (2008) Combination proteasome- and histone deacetylase (HDAC) inhibitor treatment of pancreatic cancer. Proc Am Soc Clin Onc Gastroint Canc 259Google Scholar
  10. 10.
    Cropp GF (2009) NPI-0052-103 clinical pharmacokinetics memo. Report 1035–031. MPI Inc., State College, PAGoogle Scholar
  11. 11.
    Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55PubMedCrossRefGoogle Scholar
  12. 12.
    Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 6;89(15): 1138–47Google Scholar
  13. 13.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada JNCI 93(3): 205–16Google Scholar
  14. 14.
    Miller C, Ban K, Dujka M, McConkey D, Palladino M, Chandra J (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110:267–277PubMedCrossRefGoogle Scholar
  15. 15.
    Richardson P, Hofmeister C, Jakubowiak A, Zimmerman TM, Spear MA, Palladino MA, Longenecker AM, Kelly SL, Neuteboom SN, Cropp GF, Lloyd GK, Hannah AL, Anderson KC (2009) Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM). Am. Soc HemGoogle Scholar
  16. 16.
    Badros A, Burger A, Philip S, Niesvizky R, Kolla S, Goloubeva O, Harris C, Zwiebel J, Wright J, Espinoza-Delgado I, Baer M, Holleran J, Egorin M, Grant S (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15(16):5250–5257PubMedCrossRefGoogle Scholar
  17. 17.
    Jagannath S, Siegel DS, Hajek R, Dimopoulos MA, Yoon S, Lonial S, Graef T, Lupinacci L, Reiser D, Anderson KC (2010) Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). J Clin Oncol 28:15 s, (suppl; abstr 8133)Google Scholar
  18. 18.
    Olsen EA, Kim YH, Kuzel TM et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109–3115PubMedCrossRefGoogle Scholar
  19. 19.
    Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano T, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 22:406–417CrossRefGoogle Scholar
  20. 20.
    McConkey D (2010) Proteasome and HDAC: who’s zooming who? Blood 22:308–309CrossRefGoogle Scholar
  21. 21.
    Ninan JA, Bailey H, Kolesar J, Marnocha R, Eickhoff J, Wright J, Espinoza-Delgado I, Alberti D, Wilding G, Schelman W (2009) A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol 27:15 s, (suppl; abstr 2531)Google Scholar
  22. 22.
    Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA (2010) A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res 16(1):348–357, Epub 2009 Dec 22PubMedCrossRefGoogle Scholar
  23. 23.
    Haas NB, McWhirter E, Hogg D, Martin LP, Polintan R, Litwin S, Wang L, Alpaugh RK, Zwiebel JA, Oza AM (2010) Phase II study of vorinostat in patients with advanced melanoma. J Clin Oncol 28:15 s, (suppl; abstr 8530)Google Scholar
  24. 24.
    Geyer SM, Markovic SM, Fitch TR, Albertini MR, Maples WJ, Fracasso PM , Erlichman C (2004) Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM). J Clin Oncol. Vol 22, No 14S (July 15 Supplement), 7526Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Michael Millward
    • 1
  • Timothy Price
    • 2
  • Amanda Townsend
    • 2
  • Christopher Sweeney
    • 3
  • Andrew Spencer
    • 4
  • Shawgi Sukumaran
    • 2
  • Angie Longenecker
    • 7
  • Lonnie Lee
    • 7
  • Ana Lay
    • 7
  • Girish Sharma
    • 6
  • Robert M. Gemmill
    • 6
  • Harry A. Drabkin
    • 6
  • G. Kenneth Lloyd
    • 7
  • Saskia T. C. Neuteboom
    • 7
  • David J. McConkey
    • 5
  • Michael A. Palladino
    • 7
  • Matthew A. Spear
    • 7
  1. 1.Sir Charles Gairdner HospitalUniversity of Western AustraliaPerthAustralia
  2. 2.The Queen Elizabeth HospitalAdelaideAustralia
  3. 3.Royal Adelaide HospitalAdelaideAustralia
  4. 4.The Alfred HospitalMelbourneAustralia
  5. 5.MD Anderson Cancer CenterHoustonUSA
  6. 6.Department of Medical University of South CarolinaCharlestonUSA
  7. 7.Nereus Pharmaceuticals, IncSan DiegoUSA

Personalised recommendations